Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study-Reference-Cited by-同舟云学术

Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study

Published:2024-08-09 Issue:1 Volume:22 Page:
ISSN:1477-7525
Container-title:Health and Quality of Life Outcomes
language:en
Short-container-title:Health Qual Life Outcomes

Author:

Griffiths Elizabeth A.,Min Jae S.,Lee Wei-Nchih,Yu Jeffrey C.,Patel Yogesh,Myren Karl-Johan,Dingli David

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12955-024-02279-2.pdf

Reference40 articles.

1. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–11.

2. Schrezenmeier H, Röth A, Araten DJ, Kanakura Y, Larratt L, Shammo JM, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505–14.

3. Hansen DL, Möller S, Andersen K, Gaist D, Frederiksen H. Increasing incidence and prevalence of acquired hemolytic anemias in Denmark, 1980–2016. Clin Epidemiol. 2020;12:497–508.

4. Richards SJ, Painter D, Dickinson AJ, Griffin M, Munir T, Arnold L, et al. The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population-based haematological malignancy research network 2004–2018. Eur J Haematol. 2021;107(2):211–8.

5. Jalbert JJ, Chaudhari U, Zhang H, Weyne J, Shammo JM. Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US. Blood. 2019;134(Supplement 1):3407.